Stifel Nicolaus analyst Annabel Samimy maintained a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research Report) today and set a price target ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full yea ...

Supernus Pharmaceuticals Inc (SUPN) reports robust revenue growth and strategic advancements, despite facing market ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...

(SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland-based company said it had net income of 27 cents. Earnings, adjusted for amortization ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...